TIDMSN.
RNS Number : 8639R
Smith & Nephew Plc
10 March 2021
SMITH & NEPHEW PLC
10 March 2021
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE
REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY
PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM.
On 9 March 2021, the following awards of US$0.20 ordinary shares
(the "Shares") in Smith & Nephew plc (the "Company") vested
under the Smith & Nephew Global Share Plan 2010.
1. PARTIAL VESTING ON 9 MARCH 2021 OF 2020 EQUITY INCENTIVE
PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 9
March 2020. One third of the Shares vested on 9 March 2021, a
further third will vest on 9 March 2022 and the final third will
vest on 9 March 2023. A number of Shares were sold to cover
taxation obligations arising on the vesting of the awards. The
number of Shares acquired includes the dividend equivalent Shares
which participants receive on vested Shares.
The following relates to all individuals included in the below
notification:
Reason for the notification
Initial notification Initial notification
/Amendment
----------------------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
----------------------------------------------
LEI 213800ZTMDN8S67S1H61
----------------------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
Description of the Smith & Nephew plc ordinary shares of
financial instrument, USD 0.20 each
type of instrument
----------------------------------------------
Identification code ISIN: GB0009223206
----------------------------------------------
Nature of the transaction Partial vesting of Equity Incentive Programme
awards granted on 9 March 2020 under
the Smith & Nephew Global Share Plan
2010 .
----------------------------------------------
Date of Transaction 2021 - 03 - 09
----------------------------------------------
Place of Transaction London Stock Exchange (XLON)
----------------------------------------------
Total Ordinary
Share Holding
Total Ordinary as a % of
Share Holding the Company's
following ISC following
Director Price Aggregated the transaction the transaction
Name (Position) / PDMR (GBP) Volume information * *
5,572
(of which 78,458.76313
Bradley Cannon 2,480 ordinary
(President were sold shares (including
Sports Medicine and 3,092 N/A Single 2,101.64550
& ENT) PDMR GBP13.7794 retained) Transaction in ADS') 0.00887%
---------- ------------ ---------------- -------------- ------------------- -----------------
3,729
Phil Cowdy (of which
(Chief Business 1,759
Development were sold 41,926.19975
& Corporate and 1,970 N/A Single ordinary
Affairs Officer) PDMR GBP13.7794 retained) Transaction shares 0.00474%
---------- ------------ ---------------- -------------- ------------------- -----------------
2,906
(of which
0 were
Myra Eskes sold and 11,540.94303
(President 2,906 N/A Single ordinary
APAC Region) PDMR GBP13.7794 retained) Transaction shares 0.00130%
---------- ------------ ---------------- -------------- ------------------- -----------------
3,709
Simon Fraser (of which
(President 1,104
Advanced were sold 4,583.79911
Wound and 2,605 N/A Single ordinary
Management) PDMR GBP13.7794 retained) Transaction shares 0.00052%
---------- ------------ ---------------- -------------- ------------------- -----------------
5,276
(of which
Mark Gladwell 2,489
(President were sold 5,588.44339
Operations and 2,787 N/A Single ordinary
& GBS) PDMR GBP13.7794 retained) Transaction shares 0.00063%
---------- ------------ ---------------- -------------- ------------------- -----------------
4,600
(of which
Melissa Guerdan 1,570
(Chief Quality were sold 5,581.42336
& Regulatory and 3,030 N/A Single ordinary
Affairs Officer) PDMR GBP13.7794 retained) Transaction shares 0.00063%
---------- ------------ ---------------- -------------- ------------------- -----------------
5,309
(of which
2,031
Skip Kiil were sold 7,071.53744
(President and 3,278 N/A Single ordinary
Orthopaedics) PDMR GBP13.7794 retained) Transaction shares 0.00080%
---------- ------------ ---------------- -------------- ------------------- -----------------
4,980
(of which 101,554.00000
1,967 ordinary
Elga Lohler were sold shares (including
(Chief HR and 3,013 N/A Single 3,105.00000
Officer) PDMR GBP13.7794 retained) Transaction in ADS') 0.01148%
---------- ------------ ---------------- -------------- ------------------- -----------------
4,841
Catheryn (of which 75,891.23565
O'Rourke 1,650 ordinary
(Chief Legal were sold shares (including
& Compliance and 3,191 N/A Single 5,818.25734
Officer) PDMR GBP13.7794 retained) Transaction in ADS') 0.00858%
---------- ------------ ---------------- -------------- ------------------- -----------------
4,822
Vasant (of which
Padmanabhan 1,637
(President were sold 58,796.00000
Research and 3,185 N/A Single ordinary
& Development) PDMR GBP13.7794 retained) Transaction shares 0.00664%
---------- ------------ ---------------- -------------- ------------------- -----------------
1,673
(of which
Susan Swabey 790 were 48,562.83952
(Company sold and N/A Single ordinary
Secretary) PDMR GBP13.7794 883 retained) Transaction shares 0.00549%
---------- ------------ ---------------- -------------- ------------------- -----------------
* including those held by Persons Closely Associated with the
Director/PDMR. All figures in these columns are stated to 5 decimal
places where applicable.
2. PARTIAL VESTING ON 9 MARCH 2021 OF CONDITIONAL SHARE AWARDS
MADE UNDER THE GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 9
March 2020. One third of the shares vested on 9 March 2021, a
further third will vest on 9 March 2022 and the final third will
vest on 9 March 2023. A number of Shares were sold to cover
taxation obligations arising on the vesting of the awards.
The following relates to individuals included in the below
notification:
Reason for the notification
Initial notification Initial notification
/Amendment
------------------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
------------------------------------------
LEI 213800ZTMDN8S67S1H61
------------------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
Description of the Smith & Nephew plc ordinary shares of USD
financial instrument, 0.20 each
type of instrument
------------------------------------------
Identification code ISIN: GB0009223206
------------------------------------------
Nature of the transaction Partial vesting of a Conditional Share
Award granted on 9 March 2020 under the
Smith & Nephew Global Share Plan 2010.
------------------------------------------
Date of Transaction 2021 - 03 - 09
------------------------------------------
Place of Transaction London Stock Exchange (XLON)
------------------------------------------
Total Ordinary
Share Holding
Total Ordinary as a % of
Share Holding the Company's
following ISC following
Director Price Aggregated the transaction the transaction
Name (Position) / PDMR (GBP) Volume information * *
6,546
(of which 82,090.76313
Bradley Cannon 2,914 ordinary
(President were sold shares (including
Sports Medicine and 3,632 N/A Single 2,101.64550
& ENT) PDMR GBP13.7794 retained) Transaction in ADS') 0.00928%
---------- ------------ ------------ -------------- -------------------- -----------------
4,603
Phil Cowdy (of which
(Chief Business 2,171
Development were sold 44,358.19975
& Corporate and 2,432 N/A Single ordinary
Affairs Officer) PDMR GBP13.7794 retained) Transaction shares 0.00501%
---------- ------------ ------------ -------------- -------------------- -----------------
6,594
(of which
0 were
Myra Eskes sold and 18,134.94303
(President 6,594 N/A Single ordinary
APAC Region) PDMR GBP13.7794 retained) Transaction shares 0.00205%
---------- ------------ ------------ -------------- -------------------- -----------------
5,608
(of which
Simon Fraser 1,669
(President were sold 8,522.79911
Advanced and 3,939 N/A Single ordinary
Wound Management) PDMR GBP13.7794 retained) Transaction shares 0.00096%
---------- ------------ ------------ -------------- -------------------- -----------------
6,197
(of which
Mark Gladwell 2,923
(President were sold 8,862.44339
Operations and 3,274 N/A Single ordinary
& GBS) PDMR GBP13.7794 retained) Transaction shares 0.00100%
---------- ------------ ------------ -------------- -------------------- -----------------
5,455
(of which
Melissa Guerdan 1,862
(Chief Quality were sold 9,174.42336
& Regulatory and 3,593 N/A Single ordinary
Affairs Officer) PDMR GBP13.7794 retained) Transaction shares 0.00104%
---------- ------------ ------------ -------------- -------------------- -----------------
8,029
(of which
3,072
Skip Kiil were sold 12,028.53744
(President and 4,957 N/A Single ordinary
Orthopaedics) PDMR GBP13.7794 retained) Transaction shares 0.00136%
---------- ------------ ------------ -------------- -------------------- -----------------
5,849
(of which 105,093.00000
2,310 ordinary
Elga Lohler were sold shares (including
(Chief HR and 3,539 N/A Single 3,105.00000
Officer) PDMR GBP13.7794 retained) Transaction in ADS') 0.01188%
---------- ------------ ------------ -------------- -------------------- -----------------
5,714
Catheryn (of which 79,657.23565
O'Rourke 1,948 ordinary
(Chief Legal were sold shares (including
& Compliance and 3,766 N/A Single 5,818.25734
Officer) PDMR GBP13.7794 retained) Transaction in ADS') 0.00900%
---------- ------------ ------------ -------------- -------------------- -----------------
5,610
(of which
Vasant Padmanabhan 1,904
(President were sold 62,502.00000
Research and 3,706 N/A Single ordinary
& Development) PDMR GBP13.7794 retained) Transaction shares 0.00706%
---------- ------------ ------------ -------------- -------------------- -----------------
* including those held by Persons Closely Associated with the
Director/PDMR. All figures in these columns are stated to 5 decimal
places where applicable.
Vickie Reuben
Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477410
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFSDVLIILIL
(END) Dow Jones Newswires
March 10, 2021 12:45 ET (17:45 GMT)
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Mar 2024 to Apr 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Apr 2023 to Apr 2024
